Document:

EX-10.1

 Exhibit 10.1 

TERM SHEET 
 Between

 CIPLA TECHNOLOGIES LLC 

a Delaware limited liability company, having its principal place of business at 

12220, El Camino Real, Ste 310, San Diego, CA, 92130, United States of America 

And 
 PULMATRIX INC. 

a company duly organized and existing under the laws of Delaware, having its registered office at 

99 Hayden Avenue, Suite 390, Lexington, MA 02421 

This binding term sheet (“Term Sheet”) executed on April 1st 2019 (“Effective
Date”) outlines the proposal for the establishment of a drug development arrangement between Cipla or its affiliates (hereinafter “Cipla”) and Pulmatrix Inc. (hereinafter the Company for the development and
commercialization of its inhaled Itraconazole (“PulmazoleTM”) product (the “Product”), specifically in respect of all indications related to pulmonary applications, throughout the world (the
“Territory”); this arrangement and its related processes being collectively referred to as the “Transaction”). 
 Each of
Cipla and the Company may be individually referred to herein as a “Party” and together as the “Parties”. 
  

	(i)	 STRATEGIC RATIONALE: 

Pulmatrix has developed various drug products and an intellectual property portfolio, including the iSperseTM drug delivery platform and
anti-fungal candidate PulmazoleTM, which uses the iSperseTM delivery system and is ready for Phase II clinical testing. Pulmatrix intends to conduct clinical trials and develop commercial products directed to
non-pulmonary indications (for purposes of this Term Sheet, non-pulmonary indications shall include nasal indications), as well as collaborating with Cipla to develop
PulmazoleTM Products for pulmonary indications. 
 Cipla embarked on a journey to create a specialty business in the US and played a key
role in financing and building out Chase Pharmaceuticals, an Alzheimer’s company, in Washington, DC and Irvine, CA with its subsequent sale to Allergan for a total announced value of $1 billion. In parallel to this effort, Cipla has been
developing its own specialty portfolio with the goal to create a specialty business in the US. Cipla is currently developing CPN-101, a patch formulation of Tizanidine that shortly enters phase II. This
product will address peak-trough challenges that have plagued oral therapy options. 
 Respiratory disease is Cipla’s second specialty
pillar in the US. Cipla’s heritage in respiratory is several decades old. Cipla championed the cause of inhaled steroids in many developing markets around the world including India, South Africa, parts of Africa, Asia, Middle East, South
America and pioneered the switch from oral to inhaled therapies. With an enviable range of metered dose, dry powder and breath actuated platforms, it is arguably among the top 3 producers of inhaled drugs by volume. It also licensed its IP for nasal
Azelastine Hydrochloride and Fluticasone 

  
 Page 1 of 10 

 
Propionate to Meda (now part of Mylan) that resulted in the global product Dymista. 

Cipla has an ei gh t y ( 80) year track record as a major pharmaceutical company. In February 2016, C i p l a completed a Five Hundred and
Fifty Million United States Dollars ($550 million) transaction to acquire two generic drug makers, Invagen Pharmaceuticals, Inc. and Exelan Pharmaceuticals, Inc. and Cipla is currently in the top ten (10) of the total drug volume supply to the
US. Cipla operates in over one hundred (100) countries with approximately twenty thousand (20,000) employees and in 2013, acquired Cipla Medpro South Africa Ltd., its distribution partner in South Africa, for Four Hundred and Fifty Million
United States Dollars ($ 450 million). Cipla’s top line revenue is greater than Two Billion United States Dollars ($ 2 billion), with close to Four Hundred Million United States Dollars ($360 million) in cash and cash equivalent on our balance
sheet and access to capital markets. 
 Cipla’s endeavor in the US is to target niche/orphan indications, particularly those where
critical unmet medical needs can be served by smart modifications in existing drugs through clever use of technology. The proposed disease area has a clear unmet need and the proposed solution is in Cipla’s sweet spot. Cipla, further sees, the
potential for collaboration to develop additional critically needed drugs for respiratory diseases using the combined expertise of the Company and Cipla. These will be subject to specific collaboration agreements on a case by case basis. It is
clarified that in the event the Company develops the Product in respect of indications other than those related to pulmonary applications (“Non-Indication Products”) or develops any other inhaled
anti-fungal product (“Other Drugs”), Cipla shall have a right of first refusal in respect of such Non-Indication Products and Other Drugs. 

 

	(ii)	 COMMERCIAL TERMS: 

After assessment of the commercial opportunity and the limited diligence with respect to the Product conducted by Cipla to date, Cipla
recognizes the Product’s requirement of further development and clinical trials as a prelude for commercialization. Accordingly, subject to the terms and conditions described in this Term Sheet and in other documents the Parties may execute in
the future in this connection (including any prospective development and commercialization agreement (“the Definitive Agreement”), the Parties shall execute the Transaction in the manner outlined below: 

Implementation of Clinical Development Program for the Product 

The Company shall be primarily responsible for implementing the clinical development program for the Product in accordance with (x) a
Research & Development Plan and Cost Estimate (“R&D Plan”) and (y) an Operational Plan and Budget (“Budget”), in each case, to be incorporated into the Definitive Agreement. The R&D Plan and Budget
incorporated into the Definitive Agreement have been previously provided to Cipla by the Company and both Parties have approved the contents thereof. Details of Cipla’s development costs related to the Product (the “Cipla Cost Model”)
shall also be set forth and mutually agreed upon in the Definitive Agreement. 
 Upfront Payment 

Except as set forth in Section (vi) (Consequence of a Default), within thirty (30) days from the date of execution of the Definitive
Agreement’s execution, Cipla shall make an upfront payment to the Company in the amount of Twenty Two million United States Dollars ($22,000,000) (“the Upfront 

  
 Page 2 of 10 

 
Payment”) towards an irrevocable assignment (“the Assignment”) for the Territory, of all current and future technologies, drug master files, dossiers, third party contracts and
intellectual property (the term “Intellectual Property” including but not limited to patents, proprietary information, trade secrets, brand names and copyrights) for the Product, as well as any and all other associated rights and assets
directly related to the Product, specifically in respect of indications related to pulmonary applications (“Assets”), other than the Company’s iSPERSE® technology (to which,
Cipla shall be granted a non-exclusive, perpetual, royalty-free and sub-licensable Intellectual Property license in relation to the Product). To the extent Cipla is
assigned any Assets that are directed to non-pulmonary application or indications, Cipla hereby agrees to grant to Pulmatrix an exclusive, perpetual, irrevocable, royalty-free,
sub-licenseable, and transferrable license to all Intellectual Property rights related to such assigned Assets for any non-pulmonary application or indication, including
without limitation such formulation(s), final products, and the manufacture and use of the foregoing, individually or in combination with any other active or inactive component. For the sake of clarity, (i) simultaneously upon payment of the
Upfront Payment, Cipla shall become the owner of the Assets and the license granted back to the Company will spring into effect, and (ii) the Parties shall execute, and hereby agree to execute, all documents necessary for assigning the
irrevocable ownership rights to Cipla and the irrevocable license rights granted to the Company. 
 Prior to signing of the Definitive
Agreement, Company shall demonstrate to the satisfaction of Cipla that it has at least Fifteen Million United States Dollars ($15 million) in cash, which shall be available for the development program and shall not be subject to an earlier debt
repayment condition. No lien or charge or encumbrance or mortgage shall be permitted to be created by Company or by its funding agencies or investors on the development program or the Assets. Within thirty (30) days after signing the Definitive
Agreement, Twenty Four Million United States Dollars ($24 million) shall be made available by the Company in to appropriate bank account dedicated to the development program. 

Continued Development and Commercialization 

For further development work, after $24M from the dedicated bank account is exhausted, each Party shall bear fifty percent (50%) of any costs
incurred, on actuals, with respect to the development, regulatory and commercialization (e.g., activities undertaken before and after regulatory approval of the Product that relate to the marketing, promoting, distributing and selling of the
Product) costs in respect of the Product. The net amount payable to or due from the Company will be paid quarterly or as recommended by the JDC. The Parties shall ensure continuity of the development program with availability of adequate funding
dedicated for the development program, in accordance with the requirements in R&D Plan, the Budget and the Cipla Cost Model. Company acknowledges that its technical and scientific personnel dedicated to the development program are critical to
the continuity of the development program and Company shall ensure availability of such technical and scientific capability over the development program. 

Drawing of funds 

The Parties will agree on a mechanism to set aside the funds needed for development in the
co-

  
 Page 3 of 10 

 
development phase in the bank account dedicated for the development program. This mechanism will be detailed in the Definitive Agreement. The contributions of the Parties shall be dedicated
solely for the development program and all funds draw down will be based on JDC recommendations. In connection with the development program, all payments and expenses shall be undertaken and monitored only through the specific bank account for the
development program, subject to the Budget approved by JDC. No payment of dividend or any other expenses shall be permitted from the development funds in these dedicated bank accounts. 

With regard to the development program, after $24M from the dedicated bank account is exhausted, Cipla shall contribute its share of the
development costs to a separate dedicated bank account of the Company, in which Cipla shall have a lien and the rights of first creditor in case of default by the Company and Company shall ensure that Cipla’s lien and the right as first
creditor is protected at all times. The Company shall also maintain a separate account for its share of such developments costs, which will be used solely for the development program. Cipla’s lien and right of first creditor over funds will
only be for the account dedicated for its funds and in no event will include any other funds of the Company. Promptly following the last business day of each calendar month, the Company shall provide Cipla with written documentation demonstrating
that the development costs have been funded equally from both accounts and that both accounts’ funds were used solely for the development program. 

Free Cash-Flow Sharing 

As further consideration of the Assignment Cipla and the Company shall share equally, the total Free Cash-Flow (as the definition of Free Cash
Flow to be more clearly set out under the Definitive Agreement and deductions, but is generally understood as [profit before tax (excluding Company’s share of Free Cash-Flow) from sales of the product less working capital, capital expenditure,
etc.) earned by Cipla in respect of the Product, in such manner as shall be detailed under the Definitive Agreement. 
 For clarity, the
above commercial terms are based on the assumption that upon execution of the Definitive Agreement, no payments or other obligations, in respect of the Product, shall be owed by (a) Cipla to any other third party as a result of any obligation
created by Pulmatrix or (b) Pulmatrix to any other third party as a result of any obligation created by Cipla. In general, neither Party shall incur or create any liability or obligation which would obligate the other Party for all or a portion
thereof. 
 Expenses 

Expenses incurred by either party in relation to the development program shall be defined and included in the R&D Plan, Budget and/or the
Cipla Cost Model. These expenses incurred by the Parties will be included and form part of the total development expenses. 
 Access
to Excess Contribution 
 JDC will decide the appropriate and optimal use of any excess funds arising from better management of the
development expenses by the Parties vis-à-vis the budgeted expenses. 

  
 Page 4 of 10 

	(iii)	 JOINT DEVELOPMENT COMMITTEE: 

Establishment 

Following the execution of the Definitive Agreement, the Parties shall establish a Joint Development Committee (“JDC”) to direct the
further development, regulatory and commercialization activities including all budgetary activities in respect of the Product. 
 Role

 As set forth above, the R&D Plan, Budget and Cipla Cost Model will be incorporated into the Definitive Agreement. The JDC
inter alia will also be responsible for managing and executing the R&D Plan, Budget and Cipla Cost Model for the Product. It is the intent that this JDC will be empowered to work collaboratively to make adjustments to the R&D Plan, Budget
and Cipla Cost Model as required. It is further clarified that any JDC approved escalation or decrease in the budget shall also be equally borne by the Parties on actuals. 

As with R&D Plan, Budget and Cipla Cost Model, the JDC will be responsible for developing a commercialization plan (post approval) which
will drive the free-cash flow post approval based upon agreed upon strategy, sales/marketing, capital expenditure, etc. Cipla shall be responsible for commercialization of the Product and all commercialization strategies of the Parties will be
determined by the JDC. 
 It is the intent that this JDC will be empowered to work collaboratively to make adjustments to the Development
Plan and any commercialization plan as required on an annual basis and six months in advance of each calendar year. 
 Composition

 The JDC shall comprise of four (4) persons representing Cipla and four (4) persons representing the Company. 

Deadlock 
 In case
of a deadlock, the Parties can refer the dispute to Pulmatrix CEO and Cipla Specialty Head (“Senior Executives”), for attempted resolution in good faith within thirty (30) days following notice of dispute. If a dispute cannot
be resolved by the Senior Executives, the JDC will defer to either an agreed upon binding arbitration process or panel of expert review for final decision. 
  

	(iv)	 AUDIT: 

Pulmatrix will submit to the JDC monthly reports on expenses and payments of the development program, reflecting balances of the contributions
of each Party, utilization of funds in the bank accounts and provide copies of the said reports to Cipla. Company shall make available any additional information or Management Information System(MIS) based on the reports and statements upon
reasonable requests made by Cipla. Cipla shall be entitled to conduct quarterly or need-based audits of the relevant books of accounts, records and reports of Pulmatrix and the cost of such audit shall be borne by Cipla. 

  
 Page 5 of 10 

	(v)	 REVIEW & APPROVAL: 

The Definitive Agreement shall be subject to applicable board approvals, which shall be obtained within reasonable time. 

 

	(vi)	 CONSEQUENCE OF DEFAULT 

At any time during the term of the Definitive Agreement, should either Party materially breach the Definitive Agreement as a result of its
failure to meet any of its funding/ operational obligations thereunder, (a) to the extent the breaching party has failed to cure such material breach within thirty (30) days of written notice of its occurrence from the non-breaching Party, the non- breaching Party, may at its option acquire (to the extent it is not the owner) sole ownership/ rights with respect to the Product and the Assets,
at such fair market value as may be determined by an independent third party expert, subject to an overall reduction, as shall be detailed under the Definitive Agreement; and (b) if the non-breaching
Party does not exercise its right under (a) above, all amounts receivable by the breaching party hereunder shall be subject to an overall reduction, as shall be detailed under the Definitive Agreement. 

 

	(vii)	 CIRCUMSTANCES AFFECTING CONTINUITY OF DEVELOPMENT 

In the event that: 
  

	 	(a)	 there is a failure in clinical trial, or 

 

	 	(b)	 the FDA suggests additional clinical requirements or studies that has a significant financial impact on the
total development costs, or 

  

	 	(c)	 if there is an unseen competitive event or change in law or FDA regulations resulting in commercial or
technical unviability and an adverse impact on the development program. 

 JDC shall evaluate the cause and effect of each
scenario in (a), (b) and (c) above and recommend the most optimal option available to the Parties, which may include without limitation, repeating the clinical trials, abandoning the development program or suggest ways to monetize the Assets.
Either party may, without any binding obligation, opt to follow the recommendation of JDC or decide not to opt for the recommendations of JDC. In any event, either Party may elect to terminate (a “Terminating Party”) its obligation to fund
additional costs and expenses for the development and/or commercialization of the Product. If the non-Terminating Party wishes to continue the development of the Product, then it shall have the right to
purchase the rights of the Terminating Party in the Product at fair market value as may be determined by a qualified independent third party expert acceptable to both Parties or based on external bid received on the Product by a third party and
continue with the development program either by itself or by partnering with any third party. If both Parties decide to follow the recommendation of the JDC to abandon the development program following failure or cancellation of the development
program, then the Parties shall make commercially reasonable efforts to monetize the Product and development program and agree on sharing of the proceeds based on their respective monetary contributions. For the sake of clarity, the scenarios as
described above shall not be considered an event of default and will not follow the Consequences of Default as described in clause (vii) above. 

  
 Page 6 of 10 

	(viii)	 RIGHT OF FIRST OFFER AND PROTECTION OF CIPLA’S LICENSE: 

Company shall advise Cipla in writing in the event it proposes to sell or in any manner alienate its rights in the Product (including its right
to receive 50% of Free Cash-Flow) and Cipla shall, for a period of sixty (60) days following written notice, have the right to elect to purchase such rights on such terms. The sale price shall be the fair market value of the Company’s
rights in the Product being sold or alienated, as may be determined by an independent third party expert or, if available, based on the external bid received on the Product by a third party. 

Provided however that if Cipla does not timely exercise its Right of First Offer, the Company may proceed with the sale or alienation within
mutually agreed time period (as defined in the Definitive Agreement), provided that the Company ensures that any such sale or alienation must not adversely impact Cipla’s license to such Intellectual Property or Cipla’s ability to license
such intellectual property to any third party solely to the extent necessary to utilize the Product. All rights and obligations of the respective Parties under the definitive agreement will survive any such sale of rights to a third party and shall
inure to the third party. 
 In the event that Cipla proposes to sell or in any manner alienate the Product or Assets or the intellectual
property rights in respect of the Product or Assets, Cipla shall advise the Company in writing of its intent and the Company shall for a period of sixty (60) days following written notice, have the right to confirm its decision to purchase the
Product or Assets. The sale price shall be the fair market value of Cipla’s interest in the Product, Assets or intellectual property rights being alienated, as may be determined by an independent third party expert or external bid received on
the Product by a third party. 
 Provided however that if the Company does not exercise its Right of First Offer, the Company shall ensure
that, to the extent Cipla possesses a license to such intellectual property rights, any such sale or alienation of the Product by Cipla must not adversely impact Cipla’s ability to license such intellectual property to any third party solely to
the extent necessary to utilize the Product. All rights and obligations of the respective Parties under the definitive agreement will survive any such sale of rights to a third party and shall inure to the third party. 

 

	(x)	 CONDITION PRECEDENT: 

This Proposal is subject to the condition precedent that the Company be adequately capitalized with Fifteen Million United States Dollars
($15,000,000) cumulative funds available for Pulmazole development, prior to execution of the Definitive Agreement with documented assurance to Cipla (the “Condition Precedent”). 

 

	(xi)	 ACCESS: 

Each Party shall provide to the other Party and its employees with such information as may be reasonably requested by the other party in
connection with the consummation of the transactions contemplated by this Term Sheet. All information provided by the Company hereunder shall constitute the Company’s confidential information. 

  
 Page 7 of 10 

	(xii)	 TIMETABLE 

Cipla and Pulmatrix will use commercially reasonable efforts to enter into a Definitive Agreement by the expiration of the Exclusivity Period
(as defined below). 
  

	(xiii)	 CONTACTS 

Working Group 

Chandru Chawla, 
 Executive Vice
President – Head, Specialty 
 Vikram Sudarsan, PhD 

CEO, Cipla Technologies 

Dr. Patrice Rioux, 
 Head,
Clinical Development, Cipla Technologies 
 Dr. Jaideep Gogtay, 

Senior Vice President – Head, Medical Affairs 

Ajay Luharuka, 
 Vice President
– CFO, US Specialty 
 Dr. Sudipta Ganguly, 

Director – Head, Global Respiratory Regulatory 

Carolyn Berg 
 Head of Business
Development and Commercial, US Specialty 
 Dr. Sarang Bhide, 

Associate Director – Commercial Evaluation and Transactions 

Dr. Mayur Parekh, 
 Associate
Director – Commercial Evaluation and Transactions 
 Carolyn Berg and Dr. Sarang Bhide will be point of contacts for all process
related work for this transaction. Ajay Luharuka will be a single point of contact for all transactions related negotiations. 
  

	(xiv)	 BINDING NATURE OF TERM SHEET AND DEFINITIVE AGREEMENT 

The Transaction and Term Sheet shall remain subject to the Condition Precedent, the receipt of all applicable governmental, regulatory, central
bank and other approvals, licenses and statutory compliances that may be required, negotiation on the specific terms and conditions of the Definitive Agreement and such other agreements as may be reasonably required to give effect to the Transaction
and approval of the Definitive Agreement by each party’s board of directors. Without prejudice to the provisions set forth in this Term Sheet, the Parties shall use best efforts to execute the Definitive Agreement by the expiration of the
Exclusivity Period (or such other extended date as mutually agreed in writing by the Parties), which will include additional terms 

  
 Page 8 of 10 

 
and conditions that are usual and customary for agreements of this nature, including but not limited to, representations and warranties, indemnification provisions, claims, withdrawal,
termination rights, consequences of termination, change in control, assignment, reporting and auditing, and confidentiality provisions in compliance with this Term Sheet. No amendment, alteration, modification, or waiver of this Term Sheet shall be
binding unless evidenced by an instrument in writing signed by the Party against whom enforcement thereof is sought. 
  

	(xv)	 CONFIDENTIALITY 

This Term Sheet is subject to the terms of the Confidentiality Agreement dated November 9th, 2018, executed between Cipla and the Company, it
being appreciated that any unauthorized disclosure of the terms of this Term Sheet may trigger a disclosure obligation by Cipla under applicable stock-exchange listing regulations. 

 

	(xvi)	 TRANSACTION PROCESS AND EXCLUSIVITY 

Cipla commits to allocating significant resources to ensure rapid transaction completion. Upon acceptance by the Company of this Term Sheet,
Cipla requires an exclusivity period (such period the “Exclusivity Period”) until forty five (45) days after the execution of this Term Sheet by the Company (extendable by mutual agreement) during which the Company, its affiliates,
officers, directors, employees and / or agents and / or bankers shall not initiate, engage in, or solicit indirectly or directly, or accept, any offer or proposal regarding potential acquisition of / in-
licensing of the Product by a person or entity other than Cipla. 
  

	(xvii)	 NO CONFLICTS 

The execution, delivery and performance by the Company of this Term Sheet and the Definitive Agreement and the consummation of the Transaction
contemplated hereby, do not and shall not (i) conflict with, contravene, result in a violation or breach of or default under (with or without the giving of notice or the lapse of time or both); or (ii) create in any other Person a right or
claim of termination, amendment, or require modification, acceleration or cancellation of the Transaction or any provision of the Term Sheet or the Definitive Agreement or by which any of the Assets or intellectual property rights may be bound or
affected, or any contract to which Cipla is a party or by which any of its Assets arising from this Transaction may be bound or affected. 
  

	(xviii)	 PUBLIC ANNOUNCEMENT 

The Company intends to issue a public announcement regarding the entry into to this Binding Term Sheet on or around 9:00 a.m. (local time
in New York City, New York) on Monday, April 1, 2019 (the “Initial Press Release”). The Company has previously provided the text of such public announcement to Cipla and both Parties have approved the contents thereof. Cipla and
Company agree that it will not make any public announcement regarding the entry into to this Binding Term Sheet prior to the public dissemination of the Initial Press Release. Other than with respect to the Initial Press Release, which has already
been approved by both Parties, neither Party will issue any other press release or public announcement without first providing the other Party an opportunity to review and approve the contents thereof, such approval not to be unreasonably withheld.
Cipla acknowledges that the Company may file the full text of this Binding Term Sheet 

  
 Page 9 of 10 

 
with its public reports filed with the U.S. Securities and Exchange Commission. Company acknowledges that Cipla may file the full text of this Binding Term Sheet with its public reports with the
Stock Exchange Board of India. 
  

	(xix)	 COSTS AND EXPENSES 

Each Party shall bear its respective costs and expenses in consummating the Transaction. All costs and expenses on the Term Sheet, Definitive
Agreement and any other documents executed for purposes of giving effect to the Transaction shall be borne and paid by the respective Parties. 
  

	(xx)	 GOVERNING LAW AND DISPUTE RESOLUTION 

This Term Sheet shall be governed by and construed in accordance with the laws of Delaware, without regard to conflicts of laws principles. The
Parties irrevocably agree that any dispute arising out of or in connection with this Term Sheet (including any dispute regarding the existence, validity or termination of this Term Sheet) (a “Dispute”) that remains unresolved by the Senior
Executives of the Parties for thirty (30) days and after mediation for sixty (60) days shall be referred to and finally and exclusively settled by arbitration under the American Arbitration Association (“AAA”) Rules (which Rules
are incorporated in and made a part of this Term Sheet, and the Parties hereby agree to submit to such Rules). The seat of arbitration shall be Delaware and conducted by a sole arbitrator in English language appointed in accordance with the AAA
Rules. The arbitral award shall be final, conclusive and binding on the Parties and shall be enforceable in any court of competent jurisdiction. 
  

	(xxi)	 COUNTERPARTS 

This Term Sheet may be executed by a facsimile or by scanned pdf/e-mail and by any number of
counterparts, each of which shall constitute an original and all of which taken together, shall constitute one and the same Term Sheet. 
  

	(xxii)	 CURRENCY 

As used herein “$” means United States dollars. 
  

									
		 	For Cipla Technologies, LLC	 		 		 	For Pulmatrix, Inc.
					
		 		 		 		 	
		 	Name:	 		 		 	Name:
		 	Title:	 		 		 	Title:

  
 Page 10 of 10Exhibit 4.1

 

THIS NOTE AND THE COMMON STOCK
ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT”)

 

 

US $210,000.00 

 

 

MYDX, INC

8% CONVERTIBLE REDEEMABLE NOTE

DUE MARCH 7, 2020

 

 

FOR VALUE RECEIVED, MyDx,
Inc. (the “Company”) promises to pay to the order of GS CAPITAL PARTNERS, LLC and its authorized successors and Permitted
Assigns, defined below, ("Holder"), the aggregate principal face amount Two Hundred Ten Thousand Dollars exactly
(U.S. $210,000.00) on March 7, 2020 ("Maturity Date") and to pay interest on the principal amount outstanding
hereunder at the rate of 8% per annum commencing on March 7, 2019. The Company acknowledges this Note was issued with a $3,000
original issue discount (OID) and as such the issuance price was $207,000.00. The interest will be paid to the Holder in whose
name this Note is registered on the records of the Company regarding registration and transfers of this Note. The principal of,
and interest on, this Note are payable at 30 Broad Street, Suite 1201, New York, NY 10004, initially, and if changed, last appearing
on the records of the Company as designated in writing by the Holder hereof from time to time. The Company will pay each interest
payment and the outstanding principal due upon this Note before or on the Maturity Date, less any amounts required by law to be
deducted or withheld, to the Holder of this Note by check or wire transfer addressed to such Holder at the last address appearing
on the records of the Company. The forwarding of such check or wire transfer shall constitute a payment of outstanding principal
hereunder and shall satisfy and discharge the liability for principal on this Note to the extent of the sum represented by such
check or wire transfer. Interest shall be payable in Common Stock (as defined below) pursuant to paragraph 4(b) herein. Permitted
Assigns means any Holder assignment, transfer or sale of all or a portion of this Note accompanied by an Opinion of Counsel as
provided for in Section 2(f) of the Securities Purchase Agreement.

 

This Note is subject to the
following additional provisions:

 

1.       This
Note is exchangeable for an equal aggregate principal amount of Notes of different authorized denominations, as requested by the
Holder surrendering the same. No service charge will be made for such registration or transfer or exchange, except that Holder
shall pay any tax or other governmental charges payable in connection therewith. To the extent that Holder subsequently transfers,
assigns, sells or exchanges any of the multiple lesser denomination notes, Holder acknowledges that it will provide the Company
with Opinions of Counsel as provided for in Section 2(f) of the Securities Purchase Agreement.

 

2.       The
Company shall be entitled to withhold from all payments any amounts required to be withheld under applicable laws.

 

3.       This
Note may be transferred or exchanged only in compliance with the Securities Act of 1933, as amended ("Act") and
applicable state securities laws. Any attempted transfer to a non-qualifying party shall be treated by the Company as void. Prior
to due presentment for transfer of this Note, the Company and any agent of the Company may treat the person in whose name this
Note is duly registered on the Company's records as the owner hereof for all other purposes, whether or not this Note be overdue,
and neither the Company nor any such agent shall be affected or bound by notice to the contrary. Any Holder of this Note electing
to exercise the right of conversion set forth in Section 4(a) hereof, in addition to the requirements set forth in Section 4(a),
and any prequalified prospective transferee of this Note, also is required to give the Company written confirmation that this Note
is being converted ("Notice of Conversion") in the form annexed hereto as Exhibit A. The date of receipt
(including receipt by telecopy) of such Notice of Conversion shall be the Conversion Date. All notices of conversion will be accompanied
by an Opinion of Counsel.

    1 

     

    

 

4.(a)The Holder of this Note is
entitled, at its option, at any time after the 6 month anniversary of this Note, to convert all or any amount of the principal
face amount of this Note then outstanding into shares of the Company's common stock (the "Common Stock") at a
price ("Conversion Price") for each share of Common Stock equal to 65% of the average of the two
lowest closing bid prices of the Common Stock as reported on the National Quotations Bureau OTC Marketplace exchange upon
which the Company’s shares are traded or any exchange upon which the Common Stock may be traded in the future ("Exchange")
for the fifteen prior trading days including the day upon which a Notice of Conversion is received by the
Company or its transfer agent (provided such Notice of Conversion is delivered by fax or other electronic method of communication
to the Company or its transfer agent after 4 P.M. Eastern Standard or Daylight Savings Time if the Holder wishes to include the
same day closing price). If the shares have not been delivered within 3 business days, the Notice of Conversion may be rescinded.
Such conversion shall be effectuated by the Company delivering the shares of Common Stock to the Holder within 3 business days
of receipt by the Company of the Notice of Conversion. Accrued but unpaid interest shall be subject to conversion. No fractional
shares or scrip representing fractions of shares will be issued on conversion, but the number of shares issuable shall be rounded
to the nearest whole share. To the extent the Conversion Price of the Company’s Common Stock closes below the par
value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to
the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event
the Company experiences a DTC “Chill” on its shares, the Conversion Price shall be decreased to 55% instead of 65%
while that “Chill” is in effect. In no event shall the Holder be allowed to effect a conversion if such conversion,
along with all other shares of Company Common Stock beneficially owned by the Holder and its affiliates would exceed 4.99% of the
outstanding shares of the Common Stock of the Company. All the terms set forth herein, including but not limited to interest rate,
prepayment terms, conversion discount or lookback period will be adjusted downward (i.e. for the benefit of the Holder) if the
Company offers a more favorable conversion discount (whether via interest, rate OID or otherwise) or lookback period to another
party or otherwise grants any more favorable terms to any third party than those contained herein while this note is in effect.

 

(b)       Interest
on any unpaid principal balance of this Note shall be paid at the rate of 8% per annum. Interest shall be paid by the Company in
Common Stock ("Interest Shares"). Holder may, at any time, send in a Notice of Conversion to the Company for Interest
Shares based on the formula provided in Section 4(a) above. The dollar amount converted into Interest Shares shall be all or a
portion of the accrued interest calculated on the unpaid principal balance of this Note to the date of such notice.

 

(c)       The
then outstanding principal balance of this Note may be prepaid at the following prices:

 

	PREPAY DATE	PREPAY AMOUNT
	≤ 30 days	105% of principal plus accrued interest
	31- 60 days 	110% of principal plus accrued interest
	61-90 days 	115% of principal plus accrued interest
	91-120 days 	120% of principal plus accrued interest
	121-150 days 	125% of principal plus accrued interest
	151-180 days	130% of principal plus accrued interest

 

This Note may not be prepaid after the 180th
day. Such redemption must be closed and funded within 3 days of giving notice of redemption of the right to redeem shall be null
and void.

 

(d)        Upon
(i) a transfer of all or substantially all of the assets of the Company to any person in a single transaction or series of related
transactions, (ii) a reclassification, capital reorganization (excluding an increase in authorized capital) or other change or
exchange of outstanding shares of the Common Stock, other than a forward or reverse stock split or stock dividend, or (iii) any
consolidation or merger of the Company with or into another person or entity in which the Company is not the surviving entity (other
than a merger which is effected solely to change the jurisdiction of incorporation of the Company and results in a reclassification,
conversion or exchange of outstanding shares of Common Stock solely into shares of Common Stock) (each of items (i), (ii) and (iii)
being referred to as a "Sale Event"), then, in each case, the Company shall, upon request of the Holder, redeem this
Note in cash for 150% of the principal amount, plus accrued but unpaid interest through the date of redemption, or at the election
of the Holder, such Holder may convert the unpaid principal amount of this Note (together with the amount of accrued but unpaid
interest) into shares of Common Stock immediately prior to such Sale Event at the Conversion Price.

    2 

     

    

 

(e)        In
case of any Sale Event (not to include a sale of all or substantially all of the Company’s assets) in connection with which
this Note is not redeemed or converted, the Company shall cause effective provision to be made so that the Holder of this Note
shall have the right thereafter, by converting this Note, to purchase or convert this Note into the kind and number of shares of
stock or other securities or property (including cash) receivable upon such reclassification, capital reorganization or other change,
consolidation or merger by a holder of the number of shares of Common Stock that could have been purchased upon exercise of the
Note and at the same Conversion Price, as defined in this Note, immediately prior to such Sale Event. The foregoing provisions
shall similarly apply to successive Sale Events. If the consideration received by the holders of Common Stock is other than cash,
the value shall be as determined by the Board of Directors of the Company or successor person or entity acting in good faith.

 

5.       No
provision of this Note shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal
of, and interest on, this Note at the time, place, and rate, and in the form, herein prescribed.

 

6.       The
Company hereby expressly waives demand and presentment for payment, notice of non-payment, protest, notice of protest, notice of
dishonor, notice of acceleration or intent to accelerate, and diligence in taking any action to collect amounts called for hereunder
and shall be directly and primarily liable for the payment of all sums owing and to be owing hereto.

 

7.       The
Company agrees to pay all costs and expenses, including reasonable attorneys' fees and expenses, which may be incurred by the Holder
in collecting any amount due under this Note.

 

8.       If
one or more of the following described "Events of Default" shall occur:

 

(a)       The
Company shall default in the payment of principal or interest on this Note or any other note issued to the Holder by the Company;
or

 

(b)       Any
of the representations or warranties made by the Company herein or in any agreement entered into by the Company in connection with
the execution and delivery of this Note, shall be false or misleading in any respect; or

 

(c)       The
Company shall fail to perform or observe, in any respect, any covenant, term, provision, condition, agreement or obligation of
the Company under this Note or any other note issued to the Holder; or

 

(d)       The
Company shall (1) become insolvent (which does not include a “going concern opinion); (2) admit in writing its inability
to pay its debts generally as they mature; (3) make an assignment for the benefit of creditors or commence proceedings for its
dissolution; (4) apply for or consent to the appointment of a trustee, liquidator or receiver for its or for a substantial part
of its property or business; (5) file a petition for bankruptcy relief, consent to the filing of such petition or have filed against
it an involuntary petition for bankruptcy relief, all under federal or state laws as applicable; or

 

(e)       A
trustee, liquidator or receiver shall be appointed for the Company or for a substantial part of its property or business without
its consent and shall not be discharged within sixty (60) days after such appointment; or

 

(f)       Any
governmental agency or any court of competent jurisdiction at the instance of any governmental agency shall assume custody or control
of the whole or any substantial portion of the properties or assets of the Company; or

 

(g)       One
or more money judgments, writs or warrants of attachment, or similar process, in excess of fifty thousand dollars ($50,000) in
the aggregate, shall be entered or filed against the Company or any of its properties or other assets and shall remain unpaid,
unvacated, unbonded or unstayed for a period of fifteen (15) days or in any event later than five (5) days prior to the date of
any proposed sale thereunder; or

 

    3 

     

    

(h)       Defaulted
on or breached any term of any other note of similar debt instrument in excess of $50,000 into which the Company has entered and
failed to cure such default within the appropriate grace period; or

 

(i)       The
Company shall have its Common Stock delisted from an exchange (including the OTC Markets exchange) or, if the Common Stock trades
on an exchange, then trading in the Common Stock shall be suspended for more than 10 consecutive days or ceases to file its 1934
act reports with the SEC;

 

(j)       If
a majority of the members of the Board of Directors of the Company on the date hereof are no longer serving as members of the Board;

 

(k)       The
Company shall not deliver to the Holder the Common Stock pursuant to paragraph 4 herein without restrictive legend within 3 business
days of its receipt of a Notice of Conversion which includes an Opinion of Counsel expressing an opinion which supports the removal
of a restrictive legend; or

 

(l)        The
Company shall not replenish the reserve set forth in Section 12, within 3 business days of the request of the Holder.

 

(m)       The
Company shall be delinquent in its periodic report filings with the Securities and Exchange Commission; or

 

(n)        The
Company shall cause to lose the “bid” price for its stock in a market (including the OTC marketplace or other exchange).

 

Then, or at any time thereafter, unless cured
within 10 days (except for 8(k)), and in each and every such case, unless such Event of Default shall have been waived in writing
by the Holder (which waiver shall not be deemed to be a waiver of any subsequent default) at the option of the Holder and in the
Holder's sole discretion, the Holder may consider this Note immediately due and payable, without presentment, demand, protest or
(further) notice of any kind (other than notice of acceleration), all of which are hereby expressly waived, anything herein or
in any note or other instruments contained to the contrary notwithstanding, and the Holder may immediately, and without expiration
of any period of grace, enforce any and all of the Holder's rights and remedies provided herein or any other rights or remedies
afforded by law. Upon an Event of Default, interest shall accrue at a default interest rate of 24% per annum or, if such rate is
usurious or not permitted by current law, then at the highest rate of interest permitted by law. The penalty for a breach of Section
8(n) shall be an increase of the outstanding principal amounts by 20%. Further, if a breach of Section 8(m) occurs or is continuing
after the 6 month anniversary of the Note, then the Holder shall be entitled to use the lowest closing bid price during the delinquency
period as a base price for the conversion. For example, if the lowest closing bid price during the delinquency period is $0.01
per share and the conversion discount is 50% the Holder may elect to convert future conversions at $0.005 per share.

 

If the Holder shall commence an action or proceeding
to enforce any provisions of this Note, including, without limitation, engaging an attorney, then if the Holder prevails in such
action, the Holder shall be reimbursed by the Company for its attorneys’ fees and other costs and expenses incurred in the
investigation, preparation and prosecution of such action or proceeding.

 

Make-Whole for Failure
to Deliver Loss. At the Holder’s election, if the Company fails for any reason to deliver to the Holder the conversion shares
by the by the 3rd business day following the delivery of a Notice of Conversion to the Company and if the Holder incurs a Failure
to Deliver Loss, then at any time the Holder may provide the Company written notice indicating the amounts payable to the Holder
in respect of the Failure to Deliver Loss and the Company must make the Holder whole as follows:

Failure to Deliver Loss = [(High trade price
within 20 trading days or after the day of exercise) x (Number of conversion shares)]

 

The Company must pay the Failure to Deliver
Loss by cash payment, and any such cash payment must be made by the third business day from the time of the Holder’s written
notice to the Company.

 

9.       In
case any provision of this Note is held by a court of competent jurisdiction to be excessive in scope or otherwise invalid or unenforceable,
such provision shall be adjusted rather than voided, if possible, so that it is enforceable to the maximum extent possible, and
the validity and enforceability of the remaining provisions of this Note will not in any way be affected or impaired thereby.

 

10.       Neither
this Note nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument signed by the
Company and the Holder.

    4 

     

    

 

11.       The
Company represents that it is not a “shell” issuer and that if it previously has been a “shell” issuer
that at least 12 months have passed since the Company has reported Form 10 type information indicating it is no longer a “shell
issuer.

12.       The
Company shall issue irrevocable transfer agent instructions reserving 615,384,000 shares of its Common Stock for conversions under
this Note (the “Share Reserve”). Upon full conversion of this Note, any shares remaining in the Share Reserve shall
be cancelled. The Company shall pay all transfer agent costs associated with issuing and delivering the share certificates to Holder.
If such amounts are to be paid by the Holder, it may deduct such amounts from the Conversion Price. The Company should at all times
reserve a minimum of four times the amount of shares required if the note would be fully converted.  The Holder may reasonably
request increases from time to time to reserve such amounts. The Company will instruct its transfer agent to provide the outstanding
share information to the Holder in connection with its conversions.

 

13.       The
Company will give the Holder direct notice of any corporate actions, including but not limited to name changes, stock splits, recapitalizations
etc. This notice shall be given to the Holder as soon as possible under law.

 

14.       If
it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury,
the applicable provision shall automatically be revised to equal the maximum rate of interest or other amount deemed interest permitted
under applicable law. The Company covenants (to the extent that it may lawfully do so) that it will not seek to claim or take advantage
of any law that would prohibit or forgive the Company from paying all or a portion of the principal or interest on this Note.

 

15.       This
Note shall be governed by and construed in accordance with the laws of New York applicable to contracts made and wholly to be performed
within the State of New York and shall be binding upon the successors and assigns of each party hereto. The Holder and the Company
hereby mutually waive trial by jury and consent to exclusive jurisdiction and venue in the courts of the State of New York or in
the Federal courts sitting in the county or city of New York. This Agreement may be executed in counterparts, and the facsimile
transmission of an executed counterpart to this Agreement shall be effective as an original.

 

IN WITNESS WHEREOF, the
Company has caused this Note to be duly executed by an officer thereunto duly authorized.

 

	Dated:_________	
	 	 
	 	MYDX, INC
	 	 
	 	By: 	
	 	Title:	

 

    5 

     

    

EXHIBIT A

 

 

NOTICE OF CONVERSION

 

(To be Executed by the Registered Holder in
order to Convert the Note)

 

The undersigned hereby irrevocably
elects to convert $___________ of the above Note into _________ Shares of Common Stock of MyDx, Inc. (“Shares”) according
to the conditions set forth in such Note, as of the date written below.

 

If Shares are to be issued
in the name of a person other than the undersigned, the undersigned will pay all transfer and other taxes and charges payable with
respect thereto.

 

Date of Conversion:_________________________________________________

Applicable Conversion Price:__________________________________________

Signature:________________________________________________________ 

[Print Name of Holder and Title of Signer]

Address:________________________________________________________ 

 

SSN or EIN:________________________________________________________ 

Shares are to be registered in the following name: ___________________________

 

Name:_____________________________________________________________ 

Address:___________________________________________________________ 

Tel: ______________________________________________________________ 

Fax:_______________________________________________________________ 

SSN or EIN: ________________________________________________________ 

 

Shares are to be sent or delivered to the following account:

 

Account Name:______________________________________________________

Address:___________________________________________________________

 

 

    6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]